Circulation, Vol 69, 955-962, Copyright © 1984 by American Heart Association
GS Roubin, CY Choong, S Devenish-Meares, NN Sadick, PJ Fletcher, DT Kelly and PJ Harris
Eleven patients with severe left ventricular impairment (mean ejection
fraction 24%) and moderate impairment of exercise tolerance underwent a
double-blind, placebo-controlled, cross-over trial of the orally
administered beta-agonist prenalterol. Exercise hemodynamics and tolerance
were measured during bicycle and treadmill exercise after 2 weeks of
therapy with placebo or prenalterol. Cardiac index, ejection fraction, and
stroke work index were not improved and exercise duration and peak oxygen
consumption were not significantly different during the two treatments.
During prenalterol treatment heart rate during exercise was consistently
reduced. These results show that prolonged therapy with prenalterol does
not improve hemodynamics or exercise tolerance and is associated with a
diminished heart rate response to exercise.
ARTICLES
Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol
This article has been cited by other articles:
![]() |
X.-J. Du, D. J. Autelitano, R. J. Dilley, B. Wang, A. M. Dart, and E. A. Woodcock {beta}2-Adrenergic Receptor Overexpression Exacerbates Development of Heart Failure After Aortic Stenosis Circulation, January 4, 2000; 101(1): 71 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P Steeds and K. S Channer Drug treatment in heart failure BMJ, February 14, 1998; 316(7131): 567 - 568. [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1984 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |